Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
January 29, 2026
Cell and Gene Therapy Today—January 29, 2026
January 29, 2026
Rare Diseases Today—January 29, 2026
January 28, 2026
Immunology Video Recap—January 28, 2026
January 28, 2026
Immunology Today—January 28, 2026
January 28, 2026
Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD
January 28, 2026
Neuroscience Today—January 28, 2026
January 27, 2026
Endocrinology Video Recap—January 27, 2026
January 27, 2026
Endocrinology Today—January 27, 2026
January 27, 2026
Obesity Today—January 27, 2026
January 27, 2026
Lucid Diligence Brief: Fortitude Biomedicines launch with $13M seed
January 26, 2026